Filter by:
Topic
Resource Type
Audience
Display Only
Showing 578 Results
Wage and Its Impact on Access and Adherence to Specialty Medications
Research found that lower-wage employees faced higher out-of-pocket costs, were less likely to use specialty medicines than higher-income workers and relied more regularly on emergency room care.
Expanding Pre-Deductible Coverage in HSA-Eligible Health Plans Benefits Patients
Expanding pre-deductible coverage under employer-led health plans would add few costs to health insurance premiums, according to a research report by the Employer Benefits Research Institute.
Pharmacists Can Help the Pharmaceutical Ecosystem Work Better for Patients
In a commentary, NPC President and CEO John O’Brien reflects on his personal experience as a pharmacist and how that training led him on the path to a career in health policy.
NPC Creates Guiding Principles for Designing and Evaluating Health Care Spending Research and Policies
NPC has developed principles to help evaluate health spending research.
Join NPC at ISPOR 2022
Join NPC at ISPOR 2022 for presentations and a student session and visit us at our exhibit booth.
New Moves to Shine More Light Into an Opaque Drug Pricing System
In his latest column for Chain Drug Review, NPC President and CEO John M. O’Brien points to the need for greater transparency in the pharmacy benefit manager-led rebate system.
Health Spending Post-Pandemic: Looking for High Value Beyond the Headlines
NPC Chief Science Officer Dr. Sharon Phares takes a closer look at CMS' national health expenditure report and what their predictions mean for our health care system.
Drug Price Regulation Trade-offs: Real or Imagined?
NPC hosted a panel at AcademyHealth’s National Health Policy Conference to explore the potential risks and unintended consequences of drug price regulation.
High Patient Out-of-Pocket Costs Lead to Worse Medication Adherence Without Overall Health Care Savings
Research from NPC and Xcenda suggests that high cost-sharing for prescription medications may have negative effects on patient health while not actually decreasing overall health care costs.
NPC’s John O’Brien Discusses The Myth of Average on AiArthritis Voices 360 Talk Show
On a recent episode of AiArthritis Voices 360 Podcast, John M. O’Brien discusses NPC’s research on the importance of fostering biopharmaceutical innovation and improving patient access to the right…
Continuing Innovation for Rare Conditions Under the Orphan Drug Act
The Orphan Drug Act has served as a catalyst for the development of many innovative therapies to treat rare diseases. Without the appropriate incentives to develop therapies for rare or ultra-rare…
Addressing the Needs of People Living With Autoimmune Disorders: A Conversation With Molly Murray
NPC had the opportunity to speak with Molly Murray, president and CEO of the Autoimmune Association, to learn more about the importance of understanding how individual patient differences affect the…
Women Leaders Are Making a Difference
In celebration of Women's History Month, NPC asked our women Board members to share their insights on the importance of having women in leadership and their advice to young leaders.
What If Groundbreaking Medicines Never Existed?
New research from estimates what health gains might have been lost without the introduction of influential innovations for six serious diseases.
Why Patients Are Paying More at the Pharmacy Counter in Early 2022 - And What We Can Do to Fix It
NPC Immediate Past Board Chair Mike Ryan and CSO Sharon Phares explore policy solutions to ensure patients can have predictable and affordable out-of-pocket costs for medicines.
Employers Identify Good Practices for High-Deductible Health Plans
Employers can design a smarter high-deductible health plans by following good practices identified in NPC research.
NPC Chair Shares His Outlook for an Energized Organization
In his first post as Board chair, Mallinckrodt Pharmaceuticals' Dr. Steven Romano says NPC is in a strong position to lead health policy debates through new leadership, dedicated staff experts and an…
Drug Price Controls in Medicare Part D: Not a Remedy for More Than 5 Million Medicare Beneficiaries
Proposals seeking to improve access for Medicare beneficiaries should ensure that patients are better able to get the medicines their doctors say they need.
The Certainty of Uncertainty in Health Technology Assessment
A new Health Affairs Forefront article from Tufts CEVR examines the potential flaws in how health technology assessments identify and report on uncertainty.
How Reforms Can Enable Payment Innovation That Drives Value
This NPC study models the effects of recent and proposed payment reforms related to CMS' best price reporting rules and sheds light on which approaches may encourage the adoption of value-based…